Rs964184 (APOA5-A4-C3-A1) is related to elevated plasma triglyceride levels, but not to an increased risk for vascular events in patients with clinically manifest vascular disease

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Van De Woestijne, Anton P ^a   Van Der Graaf, Yolanda ^a   De Bakker, Paul I W ^a,b,c   Asselbergs, Folkert W ^a,d   Spiering, Wilko ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; APOA5 PROTEIN, HUMAN; APOLIPOPROTEIN A; APOLIPOPROTEIN A-IV; APOLIPOPROTEIN A1; APOLIPOPROTEIN C3;

ABDOMINAL AORTA ANEURYSM; ADULT; APOA5 GENE; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PROSPECTIVE STUDY; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; AGED; ALLELE; BLOOD; GENE EXPRESSION; GENETICS; HYPERTRIGLYCERIDEMIA; MIDDLE AGED; MULTIGENE FAMILY; OBESITY; PATHOLOGY;

AGED; ALLELES; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; APOLIPOPROTEINS A; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GENE EXPRESSION; GENE FREQUENCY; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIGENE FAMILY; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TRIGLYCERIDES; VASCULAR DISEASES;

EID: 84903555267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101082     Document Type: Article

References (21)

1. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, et al. (2008) Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51: 724-730.
2. Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, et al. (2009) Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 104: 459-463.
3. van de Woestijne AP, Monajemi H, Kalkhoven E, Visseren FL (2011) Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev 12: 829-840.
4. Hegele RA, Pollex RL (2009) Hypertriglyceridemia: phenomics and genomics. Mol Cell Biochem 326: 35-43.
5. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466: 707-713.
6. Asselbergs FW, Guo Y, van Iperen EP, Sivapalaratnam S, Tragante V, et al. (2012) Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 91: 823-838.
7. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41: 56-65.
8. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40: 161-169.
9. Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, et al. (2010) Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol 30: 2264-2276.
10. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, et al. (2011) Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43: 333-338.
11. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, et al. (2013) Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45: 25-33.
12. Yin RX, Li YY, Liu WY, Zhang L, Wu JZ (2011) Interactions of the apolipoprotein A5 gene polymorphisms and alcohol consumption on serum lipid levels. PLoS One 6: e17954.
13. Lee MJ, Chien KL, Chen MF, Stephenson DA, Su TC (2013) Overweight modulates APOE and APOA5 alleles on the risk of severe hypertriglyceridemia. Clin Chim Acta 416: 31-35.
14. Gorter PM, Olijhoek JK, van der GY, Algra A, Rabelink TJ, et al. (2004) Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 173: 363-369.
15. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y (1999) Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 15: 773-781.
16. Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, et al. (2011) ESC/ EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32: 1769-1818.
17. van de Woestijne AP, Monajemi H, Kalkhoven E, Visseren FL (2011) Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev 12: 829-840.
18. Kristiansson K, Perola M, Tikkanen E, Kettunen J, Surakka I, et al. (2012) Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ Cardiovasc Genet 5: 242-249.
19. Sims EA (2001) Are there persons who are obese, but metabolically healthy? Metabolism 50: 1499-1504.
20. Nilsson SK, Heeren J, Olivecrona G, Merkel M (2011) Apolipoprotein A-V; a potent triglyceride reducer. Atherosclerosis 219: 15-21.
21. Dahabreh IJ, Kent DM (2011) Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA 305: 822-823.